Quick Answer
GoodRx Holdings, Inc. reported Cash And Cash Equivalents At Carrying Value of $261.82 million for the year ending 2025.
- GoodRx Holdings, Inc. showed a decrease of -41.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from GoodRx Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $59.69 million | Q1 2020: $95.84 million | Q2 2020: $126.63 million | Q3 2020: $1.08 billion | Q1 2021: $990.46 million | Q2 2021: $894.70 million | Q3 2021: $912.02 million | Q1 2022: $845.43 million | Q2 2022: $730.54 million | Q3 2022: $728.79 million | Q1 2023: $761.08 million | Q2 2023: $761.99 million | Q3 2023: $794.91 million | Q1 2024: $533.30 million | Q2 2024: $524.90 million | Q3 2024: $423.78 million | Q1 2025: $300.98 million | Q2 2025: $281.32 million | Q3 2025: $273.53 million.
- Over the full 8 years of available data (2018 to 2025), GoodRx Holdings, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 656.7%.
- Historical annual values: Fiscal year 2025: $261.82 million | Fiscal year 2024: $448.35 million | Fiscal year 2023: $672.30 million | Fiscal year 2022: $757.17 million | Fiscal year 2021: $941.11 million | Fiscal year 2020: $968.69 million | Fiscal year 2019: $26.05 million | Fiscal year 2018: $34.60 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: